---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000877"
form_type: "8-K"
ticker: "IRMD"
cik: "0001325618"
company_name: "IRADIMED CORP"
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:28:20.079816+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# IRADIMED reports record Q4 revenue $17.5M (+17.4%); initiates quarterly dividend; FY24 guidance $72-74M

## Summary
- Record Q4 2023 revenue $17.5M (+17.4% YoY); GAAP diluted EPS $0.36 vs $0.29, non-GAAP $0.39 vs $0.32.
- Full-year 2023 revenue $65.6M (+23% YoY); GAAP EPS $1.35, non-GAAP EPS $1.48; operating income $20.0M (+28.2%).
- Guidance Q1 2024: rev $17.0-17.3M, GAAP EPS $0.29-0.31, non-GAAP $0.33-0.35. FY2024: rev $72-74M, GAAP EPS $1.37-1.47, non-GAAP $1.52-1.62.
- CEO announces initiation of a quarterly dividend in 2024 (amount and record date not specified in release).
- Operating cash flow for FY2023 $13.5M vs $10.0M; expects ~$13M capex for new Orlando facility in 2024.

## SEC filing metadata
- accession: 0001558370-24-000877
- form_type: 8-K
- ticker: IRMD
- cik: 0001325618
- company_name: IRADIMED CORP
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1325618/000155837024000877/0001558370-24-000877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1325618/000155837024000877/irmd-20240208x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000877
- JSON: https://secwatch.observer/filing/0001558370-24-000877.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000877.txt

## Key facts
- Earnings Releases
  IRADIMED CORP reported the fourth quarter and full year ended December 31, 2023 results: revenue $17.5 million for the fourth quarter and $65.6 million for the full year of 2023, net income $4.5 million, or $0.36 per diluted share, EPS $0.36. Guidance initiated.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: $17.5 million for the fourth quarter and $65.6 million for the full year of 2023
  - Net income: $4.5 million, or $0.36 per diluted share
  - EPS: $0.36
  - Guidance: initiated
  - Result: reported results
  source text: IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results ● Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000155837024000877/0001558370-24-000877-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.